Compare Open Text Corporation (OTEX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Open Text Corporation trades at $24.96 (market cap $6.02B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Open Text Corporation is the larger of the two by market cap, and Open Text Corporation pays a 4.49% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Open Text Corporation for 24 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| OTEX | TVTX | |
|---|---|---|
Market Cap | $6.02B | $4.88B |
Volume | 1,820,095 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $39.69 | $67.52 |
52-Week Low | $20.01 | $26.79 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $11.03B | $5.01B |
Dividend Yield | 4.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OpenText (OTEX) trades at $24.95, up 3.18% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with a P/E of 9.67, robust 73.74% gross margins, and consistent earnings beats in recent quarters. Recent debt restructuring activities and strategic AI partnerships with Cohere highlight management's focus on growth optimization and technological advancement.
The outlook remains positive with a consensus price target of $28.30 offering 13% upside potential. Key risks include high debt levels and competitive pressures in the enterprise software sector. Analyst sentiment leans bullish with 42% buy ratings, though the stock faces near-term resistance at the $25 level.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
